ASH 2024 | A subset analysis of DREAMM-8: outcomes for patients who received 1 prior LOT including lenalidomide

This DREAMM-8 study has been now published in the New England Journal of Medicine and we are now presenting here early relapse patients who have received one line of therapy and most of these patients have been exposed to lenalidomide and the majority are also lenalidomide refractory which is an important feature for myeloma patients because myeloma patients are receiving lenalidomide maintenance almost for all of them and once they progress on lenalidomide these patients become candidates for a second line of therapy. And here in this DREAMM-8 study there are some patients who have been meeting this criteria and here we are reporting the results. 

The combination of belantamab, which is an antibody drug conjugate, with pomalidomide and dexamethasone comparing with pomalidomide, bortezomib, and dexamethasone, the difference in outcome has been shown earlier with a significant impact on progression-free survival. And this data is valid for patients who are receiving this combination after the first line and the differences are valid for in terms of PFS, in terms of depth of response almost doubling the CR rate and also MRD negativity. So measurable residual disease is like 33% among patients who have received belantamab versus those who did not receive which is like 5%. So the difference is really very big. 

And the major concern about the ocular toxicity of belantamab has been addressed in detail. And 92% of patients have reversible ocular toxicity. And this is a very important finding. And once we recognize these ocular toxicities, we stop or modify the dosing and increase the intervals. And what we have seen is increasing the intervals does not impair the response, and so the response is durable and the toxicity is manageable.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.